Merck said Keytruda (pembrolizumab) significantly improved progression-free survival versus standard platinum-doublet chemotherapy in the Phase III KEYNOTE-C93 trial in mismatch repair deficient advanced or recurrent endometrial cancer, marking what the company says is the first Phase III win for PD-1 monotherapy over chemo in this setting. At interim analysis, the study hit its primary PFS endpoint and showed a trend toward improved overall survival, with results slated for presentation at an upcoming medical meeting and regulatory submission.

Why It Matters To Oncology

• The readout supports a potential frontline chemo-free option for patients with dMMR advanced or recurrent endometrial cancer.

• If confirmed in full data, the result could further validate biomarker-selected immunotherapy monotherapy earlier in the treatment pathway.

• The finding is especially relevant for clinicians weighing efficacy, tolerability and treatment sequencing against platinum-based regimens.

The Financials

• No new revenue guidance or deal value was disclosed with the trial update.

• For Merck, a label expansion in frontline endometrial cancer could extend Keytruda's reach in a high-value immuno-oncology market.

• Regulatory filings after the upcoming data presentation could create a new commercial opportunity in a biomarker-defined population.

What They're Saying

• Merck said KEYNOTE-C93 significantly improved PFS over chemotherapy and delivered clinically meaningful overall and complete response rates with durable responses.

• Principal investigator Brian Slomovitz said the findings could pave the way for a potential chemo-free treatment option in the frontline setting.

• The company also said overall survival data remain immature despite an early trend toward improvement.

What's Next

• Investigators plan to present full KEYNOTE-C93 data at an upcoming medical meeting.

• Merck said it will submit the results to regulators, setting up a possible filing for this endometrial cancer use.

• Clinicians will want to see hazard ratios, subgroup performance, safety details and quality-of-life data before judging practice-changing potential.